Stockreport

How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk [Yahoo! Finance]

Pulmonx Corporation  (LUNG) 
US:NASDAQ Investor Relations: investor.prolunginc.com/investor-relations
PDF Pulmonx now sits under a reset US$5 price target, with the fair value estimate holding at US$5.17 per share, signalling that the core valuation framework has not been r [Read more]